ION expands ETF trading capabilities with Tradeweb integration
Director John S. Montalbano of AbCellera Biologics Inc (NASDAQ:ABCL) acquired 50,000 common shares of the company on November 26, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were purchased at a price of $3.5692, totaling $178,460. The purchase comes as InvestingPro data shows ABCL’s stock has gained 83.8% over the past six months, though the RSI currently suggests the stock is in oversold territory.
Following the transaction, Montalbano directly owns 221,000 common shares and indirectly owns 5,000 shares by spouse. AbCellera, with a market capitalization of approximately $1.07 billion, maintains a strong liquidity position with a current ratio of 10.1 and holds more cash than debt on its balance sheet. The company’s overall financial health is rated as "FAIR" by InvestingPro, which offers additional insights through its comprehensive Pro Research Report, one of 1,400+ available for top US equities.
In other recent news, AbCellera Biologics Inc. has initiated a Phase 1 clinical trial for ABCL575, an investigational antibody therapy aimed at treating moderate-to-severe atopic dermatitis. This therapy targets the OX40 ligand and is designed with features that may allow for dosing every six months, potentially offering an advantage over other therapies currently in development. Additionally, the company has appointed Sarah Noonberg as its first Chief Medical Officer. Dr. Noonberg brings over 20 years of experience in leading development programs across various therapeutic areas, including oncology and gene therapy. In another leadership update, AbCellera has added Stephen Quake to its Board of Directors as an independent director. Dr. Quake, a renowned scientist, holds positions at Stanford University and has been recognized by several prestigious national academies. These developments reflect AbCellera’s continued focus on enhancing its leadership and advancing its clinical programs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.